TY - JOUR
T1 - Heparin-Conjugated Decellularized Bone Particles Promote Enhanced Osteogenic Signaling of PDGF-BB to Adipose-Derived Stem Cells in Tissue Engineered Bone Grafts
AU - Rindone, Alexandra N.
AU - Kachniarz, Bartlomiej
AU - Achebe, Chukwuebuka C.
AU - Riddle, Ryan C.
AU - O'Sullivan, Aine N.
AU - Dorafshar, Amir H.
AU - Grayson, Warren L.
N1 - Funding Information:
This work was supported by the National Science Foundation Graduate Research Fellowship (A.N.R.) and Maryland Stem Cell Research Fund 2014-MSCRFI-0699 (W.L.G.). Confocal imaging was performed at the Wilmer Microscopy and Imaging Core Facility under NIH P30 Grant No. EY001765. Special thanks to Dr. Feilim Mac Gabhann for his advice in designing the binding kinetics model, Dr. Sven Sommerfeld for his advice in initially designing the growth factor delivery system, and Athenia Jones in helping with the preliminary stages of this project.
Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019/5/23
Y1 - 2019/5/23
N2 - Adipose-derived stem cells (ASCs) are a promising cell source for regenerating critical-sized craniofacial bone defects, but their clinical use is limited due to the supraphysiological levels of bone morphogenetic protein-2 required to induce bone formation in large grafts. It has been recently reported that platelet-derived growth factor-BB (PDGF) directly enhances the osteogenesis of ASCs when applied at physiological concentrations. In this study, a biomimetic delivery system that tethers PDGF to decellularized bone matrix (DCB) is developed to enhance osteogenic signaling in bone grafts by colocalizing PDGF-extracellular matrix cues. Heparin is conjugated to DCB particles (HC-DCB) to promote sustained binding of PDGF via electrostatic interactions. HC-DCB particles bind to PDGF with >99% efficiency and release significantly less PDGF over 21 days compared to nonconjugated DCB particles (1.1% vs 22.8%). HC-DCB-PDGF signaling in polycaprolactone (PCL)-fibrin grafts promotes >40 µg Ca2+ µg−1 DNA deposition by ASCs during in vitro osteogenic culture compared to grafts without HC-DCB or PDGF. Furthermore, more bone formation is observed in grafts with HC-DCB-PDGF at 12 weeks following implantation of grafts into murine critical-sized calvarial defects. Collectively, these results demonstrate that HC-DCB enhances the osteogenic signaling of PDGF to ASCs and may be applied to promote ASC-mediated bone regeneration in critical-sized defects.
AB - Adipose-derived stem cells (ASCs) are a promising cell source for regenerating critical-sized craniofacial bone defects, but their clinical use is limited due to the supraphysiological levels of bone morphogenetic protein-2 required to induce bone formation in large grafts. It has been recently reported that platelet-derived growth factor-BB (PDGF) directly enhances the osteogenesis of ASCs when applied at physiological concentrations. In this study, a biomimetic delivery system that tethers PDGF to decellularized bone matrix (DCB) is developed to enhance osteogenic signaling in bone grafts by colocalizing PDGF-extracellular matrix cues. Heparin is conjugated to DCB particles (HC-DCB) to promote sustained binding of PDGF via electrostatic interactions. HC-DCB particles bind to PDGF with >99% efficiency and release significantly less PDGF over 21 days compared to nonconjugated DCB particles (1.1% vs 22.8%). HC-DCB-PDGF signaling in polycaprolactone (PCL)-fibrin grafts promotes >40 µg Ca2+ µg−1 DNA deposition by ASCs during in vitro osteogenic culture compared to grafts without HC-DCB or PDGF. Furthermore, more bone formation is observed in grafts with HC-DCB-PDGF at 12 weeks following implantation of grafts into murine critical-sized calvarial defects. Collectively, these results demonstrate that HC-DCB enhances the osteogenic signaling of PDGF to ASCs and may be applied to promote ASC-mediated bone regeneration in critical-sized defects.
KW - adipose-derived stem cells
KW - bone extracellular matrix
KW - bone tissue engineering
KW - growth factor delivery
KW - platelet-derived growth factors
UR - http://www.scopus.com/inward/record.url?scp=85063791960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063791960&partnerID=8YFLogxK
U2 - 10.1002/adhm.201801565
DO - 10.1002/adhm.201801565
M3 - Article
C2 - 30941920
AN - SCOPUS:85063791960
SN - 2192-2640
VL - 8
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 10
M1 - 1801565
ER -